<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04553796</url>
  </required_header>
  <id_info>
    <org_study_id>non alcoholic fatty liver</org_study_id>
    <nct_id>NCT04553796</nct_id>
  </id_info>
  <brief_title>Assessment of Nonalcoholic Fatty Liver Disease in Diabetic and Prediabetic Patients Using Noninvasive Methods.</brief_title>
  <official_title>Assessment of Nonalcoholic Fatty Liver Disease in Diabetic and Prediabetic Patients Using Noninvasive Methods.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      assessment of NAFLD among diabetic, pre-diabetic and non diabetic participants Using Non&#xD;
      Invasive Methods.And correlation between lab and radiological methods .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non alcoholic fatty liver disease (NAFLD) is a major public health problem. with 10-30%&#xD;
      prevalence worldwide , and is a common cause of chronic liver disease and the third most&#xD;
      common cause of liver transplantation .&#xD;
&#xD;
      NAFLD can range from simple steatosis in the absence of inflammation to nonalcoholic&#xD;
      steatohepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) .&#xD;
&#xD;
      Major risk factors for NAFLD include obesity, hypertension , hyperlipidemia ,&#xD;
      hypertriglyceridemia , and type-2-diabetes mellitus (T2DM) .&#xD;
&#xD;
      The gold standard in the diagnosis of NAFLD is liver biopsy; however, it is sometimes&#xD;
      associated with some complications that include bleeding, bile leak, infection, and other&#xD;
      potential life-threatening issues. The accuracy of the MRI, computed tomography, and&#xD;
      ultrasound imaging in diagnosis of NAFLD is low; hence, Fibroscan was introduced .&#xD;
&#xD;
      This is a non-invasive, simple-to-perform imaging modality with high accuracy to assess liver&#xD;
      stiffness and hepatic fat deposition. Non-invasive diagnosis is based on clinical and&#xD;
      biochemical markers, scoring models, and algorithms of methods which have sufficient&#xD;
      sensitivity, specificity, and reproducibility .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>correlation between lab and radiological methods</measure>
    <time_frame>2 days</time_frame>
    <description>results of fibroscan, lab investigations include Complete blood picture Fasting plasma glucose (FBG) and Glycated hemoglobin (HbA1C) Liver function tests including ( serum bilirubin , serum albumin , ALT , AST , ALP , prothrombin time and INR ) kidney function tests. Lipid profile including (serum cholesterol and triglycerides ). hepatitis marker (HBs Ag , Anti-HCV Ab). and NAFLD Fibrosis Score will be correlated</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Non Alcoholic Fatty Liver</condition>
  <arm_group>
    <arm_group_label>diabetic participants</arm_group_label>
    <description>HBA1C : 6.5% or higher Fasting Plasma Glucose : 126 mg/dl or higher Oral Glucose Tolerance Test : 200 mg/dl or higher Random Plasma Glucose Test : greater than or equal to 200 mg/dl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prediabetic participants</arm_group_label>
    <description>HBA1C : 5.7% to 6.4% Fasting Plasma Glucose : 100 mg/dl to 125 mg/dl Oral Glucose Tolerance Test : 140 mg/dl to 199 mg/dl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non diabetic participants</arm_group_label>
    <description>HBA1C : less than 5.7% Fasting Plasma Glucose : less than 100 mg/dl Oral Glucose Tolerance Test : less than 140 mg/dl</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>fibroscan</intervention_name>
    <description>Fibroscan is a non-invasive test that helps assess the health of your liver. Specifically, it uses ultrasound technology to determine the degree of fibrosis or scarring that may be present in your liver from various liver diseases or conditions</description>
    <arm_group_label>diabetic participants</arm_group_label>
    <arm_group_label>non diabetic participants</arm_group_label>
    <arm_group_label>prediabetic participants</arm_group_label>
    <other_name>Transient Elastography</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        participants older than 18 years with no definite cause of nafld in our out patient clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  the participants are divided into 3 groups: the diabetic group patients (T2DM) ,the&#xD;
             pre-diabetic and the non diabetic one. The diagnosis will be according to the American&#xD;
             Diabetes Association (ADA) clinical practice recommendations-2019&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients under the age of 18.&#xD;
&#xD;
          -  patients with viral hepatitis (HBV - HCV).&#xD;
&#xD;
          -  Subjects with risk of 2nd hepatic steatosis liver disease (excessive alcohol&#xD;
             consumption and medications).&#xD;
&#xD;
          -  history of liver disease such as (α-1 antitrypsin deficiency, autoimmune hepatitis,&#xD;
             drug-induced liver injury, 1ry biliary cirrhosis, 1ry sclerosing cholangitis).&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 35 (to avoid the possibility of Fibroscan failure).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>lobna a ahmed, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael m Fekry, doctor</last_name>
    <phone>+201207601294</phone>
    <email>mesho0js@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>lobna f eltoony, professor</last_name>
    <phone>+201005571004</phone>
    <email>leltoni@aun.edu.eg</email>
  </overall_contact_backup>
  <reference>
    <citation>European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7.</citation>
    <PMID>27062661</PMID>
  </reference>
  <reference>
    <citation>Lv S, Jiang S, Liu S, Dong Q, Xin Y, Xuan S. Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2018 Jun 28;6(2):217-221. doi: 10.14218/JCTH.2018.00021. Epub 2018 Jun 22. Review.</citation>
    <PMID>29951367</PMID>
  </reference>
  <reference>
    <citation>Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine J, Tonascia J, Loomba R. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care. 2015 Jul;38(7):1347-55. doi: 10.2337/dc14-1239. Epub 2015 Apr 17.</citation>
    <PMID>25887357</PMID>
  </reference>
  <reference>
    <citation>Dharmalingam M, Yamasandhi PG. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Indian J Endocrinol Metab. 2018 May-Jun;22(3):421-428. doi: 10.4103/ijem.IJEM_585_17. Review.</citation>
    <PMID>30090738</PMID>
  </reference>
  <reference>
    <citation>Esterson YB, Grimaldi GM. Radiologic Imaging in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Liver Dis. 2018 Feb;22(1):93-108. doi: 10.1016/j.cld.2017.08.005. Epub 2017 Oct 10. Review.</citation>
    <PMID>29128063</PMID>
  </reference>
  <reference>
    <citation>de Lédinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012 Jul;32(6):911-8. doi: 10.1111/j.1478-3231.2012.02820.x.</citation>
    <PMID>22672642</PMID>
  </reference>
  <reference>
    <citation>Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019 Apr;156(5):1264-1281.e4. doi: 10.1053/j.gastro.2018.12.036. Epub 2019 Jan 18. Review.</citation>
    <PMID>30660725</PMID>
  </reference>
  <reference>
    <citation>Sheth H, Bagasrawala S, Shah M, Ansari R, Olithselvan A, Lakdawala M. The HAALT Non-invasive Scoring System for NAFLD in Obesity. Obes Surg. 2019 Aug;29(8):2562-2570. doi: 10.1007/s11695-019-03880-x.</citation>
    <PMID>31016455</PMID>
  </reference>
  <reference>
    <citation>Wang CC, Jhu JJ. On the Application of Clustering and Classification Techniques to Analyze Metabolic Syndrome Severity Distribution Area and Critical Factors. Int J Environ Res Public Health. 2019 May 6;16(9). pii: E1575. doi: 10.3390/ijerph16091575.</citation>
    <PMID>31064061</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28. doi: 10.2337/dc19-S002. Review.</citation>
    <PMID>30559228</PMID>
  </reference>
  <reference>
    <citation>Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007 Apr;45(4):846-54.</citation>
    <PMID>17393509</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 12, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>December 19, 2020</last_update_submitted>
  <last_update_submitted_qc>December 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Michael Melad Fekry Endrawes</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

